LakeShore Biopharma Co (LakeShore Biopharma Co) Common Stock : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Common Stock?

LakeShore Biopharma Co's quarterly common stock increased from Sep. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) but then stayed the same from Mar. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

LakeShore Biopharma Co's annual common stock stayed the same from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($0.00 Mil) but then increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil).

LakeShore Biopharma Co Common Stock Historical Data

The historical data trend for LakeShore Biopharma Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Common Stock Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Common Stock

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Common Stock	Get a 7-Day Free Trial			-	-	-	-	-

LakeShore Biopharma Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.